Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Plegridy Market Growth Analysis: How Will Revenue Expand During The Forecast Period?
The rise observed during the historic period was driven by several factors, including a higher frequency of multiple sclerosis diagnoses, the accessibility of treatments based on interferon, the proliferation of specialized neurology clinics, an increase in injectable biologic therapies, and the approval of pegylated treatments by regulatory bodies.
The anticipated expansion during the forecast period is driven by a heightened need for better patient adherence tools, greater funding directed toward multiple sclerosis medication development, the broadening scope of individualized neurological treatments, an intensified emphasis on sustained disease control, and progress in biologic drug administration methods. Key developments expected in this timeframe encompass a surge in the use of extended-release MS therapies, a growing preference for therapies requiring fewer injections, an increased prioritization of disease-modifying medications, the growth of treatment approaches centered on patient needs, and more sophisticated tracking of therapeutic results.
Download A Free Sample Report For Comprehensive Market Insights:
Plegridy Market Development Factors: Which Trends Are Supporting Demand?
The rising prevalence of multiple sclerosis is anticipated to fuel expansion in the plegridy market in the coming period. Multiple sclerosis is a chronic autoimmune condition where the immune system erroneously targets myelin, the protective coating around nerve fibers in the central nervous system, thereby impairing communication between the brain and the body and giving rise to various neurological symptoms. This increased prevalence stems from factors such as environmental influences, enhanced diagnostic methods, greater disease awareness and recognition, and lifestyle shifts—including obesity and vitamin D deficiency—especially among women. Plegridy is administered to multiple sclerosis patients to lower relapse rates and decelerate disease progression through immune system modulation. For example, in May 2024, a report from the Multiple Sclerosis Trust, a UK-based national charity, indicated that over 150,000 individuals in the UK have multiple sclerosis, with more than 7,100 new diagnoses occurring annually. Moreover, multiple sclerosis cases have risen by up to 15% across various regions, with diagnoses most common in people in their 30s and 40s. Hence, the growing incidence of multiple sclerosis is propelling the plegridy market forward.
The anticipated rise in healthcare spending is expected to drive growth in the plegridy market going forward. Healthcare spending encompasses total expenditures on medical goods and services, such as personal healthcare, preventive services, public health programs, and health administration, all aimed at improving health outcomes. This increase is fueled by population expansion, an aging demographic, a higher prevalence of chronic diseases, and escalating costs for medical services and prescription drugs. Greater healthcare spending enhances plegridy adoption by widening treatment access, boosting patient knowledge, and strengthening healthcare infrastructure for multiple sclerosis care. For instance, in August 2023, a report from the National Health Service Confederation, a UK-based membership organization, revealed that for the 2022-23 fiscal year, NHS England received $152.6 billion in funding, with over 70% of that—$107.8 billion—allocated to integrated care boards. Consequently, rising healthcare spending is a key driver of the plegridy market’s growth.
The growing use of biologics is expected to propel the expansion of the plegridy market in the future. Biologics are sophisticated medications derived from living organisms, such as proteins and antibodies, employed to treat diverse diseases by precisely targeting biological pathways in the body. Their increased adoption is driven by their efficacy in treating various illnesses, progress in biotechnology, and a rising demand for targeted therapies that address complex health issues. In multiple sclerosis care, biologics have fostered plegridy’s growth by providing a more precise, potent, and convenient treatment alternative for patients. For example, in August 2025, the National Institutes of Health (NIH), a US-based biomedical research agency, reported that in 2024, the FDA approved 50 new medicines, including 16 biologics, with six of those biologic approvals occurring in the year’s first half. Therefore, the greater utilization of biologics is fueling the growth of the plegridy market.
Plegridy Market Segment Breakdown: Which Categories Generate The Most Revenue?
The plegridy market covered in this report is segmented –
1) By Roue Of Administration: Subcutaneous (SC) Injection, Intramuscular (IM) Injection
2) By Clinical Indication: Relapsing-Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS) With Relapses
3) By Distribution Channel: Direct Sales, Online Pharmacies, Wholesale Distributors
4) By End User: Hospitals, Clinical Research Laboratories
Plegridy Market Key Players And Strategic Industry Positioning
Major companies operating in the plegridy market are Biogen Inc.
Access The Complete Plegridy Market Report:
Plegridy Market Regional Distribution: Which Areas Drive Market Expansion?
North America was the largest region in the plegridy market in 2025. The regions covered in the plegridy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model